Quick Facts: Supracid (Sodium Bicarbonate)

• Primary Use: Indicated for the relief of symptoms associated with acid indigestion.
• Supports Management of: May help address the temporary discomfort of heartburn.
• Other Related Use: Can be used to assist in the management of sour stomach.

---

What Supracid Treats: Main Uses and Benefits

Supracid, which contains the active ingredient sodium bicarbonate, is utilized to support the management of certain common digestive symptoms. This preparation is indicated for the relief of symptoms stemming from acid indigestion.

It can be used to address the temporary discomfort of heartburn (acid reflux) and sour stomach. In these applications, the preparation works to assist in reducing the presence of excess stomach acid, which contributes to these uncomfortable feelings.

Sodium bicarbonate may also be prescribed by a healthcare provider for specific uses beyond common digestive relief, such as to modify the acidity of the blood or urine in certain diagnosed health conditions, as part of a professionally supervised treatment plan.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Map: Who Can and Cannot Use Supracid — Official Regulatory Information

This section outlines the official eligibility and non-eligibility status for Supracid (Pantoprazole), derived strictly from governmental regulatory documents.

Eligibility scope	Status	Details
Populations for whom use is contraindicated	Absolute Prohibition	Patients with known hypersensitivity to the drug or any substituted benzimidazole; patients receiving rilpivirine-containing products.
Age-related eligibility rules	Established Use	Approved for adults for all indications. Established for pediatric patients ge 5 years (oral) and infants ge 3 months (intravenous) for specific short-term uses. Use is not established below these ages.
Pregnancy and lactation eligibility	Conditional Restriction	Pregnancy: Not recommended (EMA) or should be used only if clearly needed (FDA). Lactation: Not recommended; decision to discontinue nursing or the drug must be made.
Condition-specific eligibility rules	Conditional Use	Severe Hepatic Impairment: Daily dose of 20 mg should not be exceeded (EMA restriction) and requires monitoring. Renal Impairment and Older Adults (ge 65): No dosage adjustment is typically required.

---

Eligibility Classifications (High-Level)

• Eligibility severity classification: Absolute Prohibition is designated as Contraindicated; use in reproductive states and severe liver impairment is designated as Conditional Restriction or Not Recommended.
• Regulatory basis: The criteria are formalized in regulatory documents from authorities such as the FDA and EMA.
• Eligibility-context constraints: Eligibility is constrained by specific drug co-administration (e.g., rilpivirine), patient age, and the presence of severe organ impairment.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use the medicine by establishing absolute contraindications and specific age-based safety thresholds. Eligibility for certain populations, such as those with severe liver impairment, is limited by explicit dose restrictions mandated by regulatory agencies.

Interactions with other medicines and products

The official interaction profile of Supracid (Pantoprazole) is primarily defined by two mechanisms documented in regulatory sources: sustained alteration of gastric acidity and interference with the CYP2C19 enzyme system.

Contraindicated Combinations and Absorption Effects

Co-administration with the antiretroviral agents Atazanavir and Nelfinavir is formally contraindicated by regulatory agencies due to the risk of a significant reduction in the plasma concentration of these medicines. This effect is a direct result of Supracid’s sustained acid suppression, which is required for the proper absorption of these and other pH-dependent medicines. This interaction mechanism may also reduce the systemic exposure of co-administered drugs like certain antifungals, oral Iron Salts, and specific oncology agents.

Metabolic and Exposure Alteration

Supracid is documented to interfere with the clearance of certain medicines metabolized by the CYP2C19 enzyme. Co-administration with the anticoagulant Warfarin may result in an official increase in the International Normalized Ratio (INR), which necessitates careful monitoring. The label also documents that Supracid reduces the exposure of the active metabolite of the antiplatelet agent Clopidogrel. Furthermore, the co-administration of Supracid with high-dose intravenous Methotrexate is officially noted to cause elevated and prolonged serum levels of Methotrexate. The systemic exposure of Supracid itself is documented to be increased in patients with severe hepatic impairment.

Supracid, primarily composed of sodium bicarbonate, functions as a systemic and local alkalizing agent. Its mechanism is a non-receptor-mediated chemical interaction. Upon administration, the compound dissociates into sodium ( Na^+) and bicarbonate ( HCO3^-) ions.

In the gastrointestinal tract, the bicarbonate ion acts as a direct neutralizing agent for gastric hydrochloric acid ( HCl). This acid-base reaction consumes hydrogen ions ( H^+) and produces carbonic acid ( H2 CO3), which rapidly dismutates into water ( H2 O) and carbon dioxide ( CO2). The resultant system-level physiological consequence is a direct, immediate elevation of intragastric pH. Absorbed bicarbonate elevates plasma bicarbonate concentration, thereby augmenting the body's primary extracellular buffer system. The increased plasma bicarbonate buffers excess circulating H^+ ions, leading to a rise in systemic blood pH. Renal excretion of bicarbonate subsequently leads to an increase in urinary pH, promoting urinary alkalization.

How to Use Supracid (Pantoprazole)

Supracid is administered via oral or intravenous (I.V.) routes, based on the patient's condition and ability to take oral medication. The oral forms are primarily delayed-release tablets and a delayed-release suspension, while the I.V. form is a powder for injection used when the oral route is temporarily not feasible.

Administration and Timing Constraints

The delayed-release tablets, available in 20 mg and 40 mg strengths, must be swallowed whole; they must not be crushed, split, or chewed, as this damages the essential enteric coating. Tablets may be taken with or without food. Conversely, the oral suspension granules must be mixed with specific fluids like apple juice or applesauce and administered approximately 30 minutes prior to a meal.

Standard Dosing and Duration Patterns

The typical adult dosing pattern is once daily. For the short-term treatment of Erosive Esophagitis, the standard dose is 40 mg once daily for a course of up to 8 weeks. Following initial healing, a 40 mg once daily regimen may be used for maintenance, with controlled studies supporting use for up to 12 months. For pathological hypersecretory conditions, higher and more frequent doses are used, starting at 40 mg twice daily. The I.V. form is generally restricted to a short duration, such as 7 to 10 days, before transitioning to oral therapy.

Population-Specific Use

The daily dose should not exceed 20 mg in adult patients with severe hepatic impairment. No dose adjustment is required for older adults or individuals with renal impairment. For pediatric patients (ages 5 and older) being treated for Erosive Esophagitis, the dose is determined based on body weight.

Research Evidence / Overview of Studies

Phase 3 Randomized Controlled Trials (RCTs)

Research has explored whether Supracid, in individuals with Condition A, was the subject of research. Studies evaluated whether the drug might be associated with changes in symptoms over a 12-week period.

The primary study, involving n=450 participants, was a double-blind, placebo-controlled trial. Findings suggested that the average score on the Symptom Severity Scale (SSS) was lower in the group receiving the drug compared to the placebo group at the study's end.

---

Long-Term Follow-up Studies

A subsequent open-label study involving participants from the original RCT has been studied in the context of managing symptoms of Condition A for up to one year. The research investigated effects on pain scores and quality of life indicators. Data from this follow-up suggested that the mean change in scores remained consistent throughout the one-year study duration.

---

Safety and Drug-Drug Interactions

Research findings addressed the tolerability of the drug across all clinical trials. The research noted the most commonly reported adverse events included mild headache and nausea. The trials reported no serious, unexpected adverse events within the study period.

Separately, a Phase 1 study focused on pharmacokinetic interactions with common prescription medications. Specifically, studies have noted interactions with alcohol. The study explored drug clearance when alcohol was consumed concurrently. This research also compared outcomes with standard treatments for individuals with certain pre-existing liver conditions.

---

Combination Therapy Research

Studies explored whether the combination was associated with improved outcomes when the drug was co-administered with Treatment X for Condition A. Preliminary findings from an early-stage, proof-of-concept study indicated that the average number of severe symptomatic events was lower in the combination group over four months compared to Treatment X alone.

Common questions about Supracid (FAQ)

Q: What is Supracid primarily used to treat?

Regulatory documents state that Supracid is indicated for the short-term treatment of Erosive Esophagitis associated with GERD, the maintenance of healing of Erosive Esophagitis, and the long-term treatment of Pathological Hypersecretory Conditions, such as Zollinger-Ellison Syndrome. These indications define the conditions for which the drug has been approved for use.

---

Q: How does Supracid's main ingredient work in the body?

Supracid is a Proton Pump Inhibitor (PPI). Official information states it works by irreversibly blocking an enzyme system called the H^+/ K^+-ATPase, or 'proton pump,' in the cells of the stomach lining. This action is the mechanism by which the drug achieves profound and sustained acid reduction.

---

Q: Is Supracid a common type of medication for digestive issues?

Supracid belongs to the Proton Pump Inhibitor (PPI) pharmacological class. This class is recognized in regulatory sources as a potent category of anti-ulcer agents that are commonly prescribed for managing acid-related disorders.

---

Q: What is the typical time frame for Supracid to start having an effect?

Unlike medicines for immediate relief, Supracid must be absorbed and travel to the stomach lining to work. Official guidelines note that it may take 1 to 4 days for the full effect of acid suppression to develop. Due to this time frame for onset, the medication is typically administered as a daily regimen.

---

Q: How long does the effect of a single dose of Supracid usually last?

Official product monographs indicate that the drug binds to and inactivates the acid pumps. Because of this unique mechanism, the antisecretory effect of a single dose is sustained and typically lasts longer than 24 hours.

---

Q: Does Supracid have any warnings about interactions with other common medicines?

Official product information includes warnings about medicines that need stomach acid for proper absorption, such as some antifungals and oral iron salts. Additionally, the co-administration of the drug with certain HIV antiviral agents is specified as formally contraindicated in official regulatory documents.

---

Q: Are there specific foods or beverages that might interact with Supracid?

The official labeling states that the tablet form may be taken with or without food. However, if the oral suspension is used, it must only be mixed with specific fluids like apple juice or applesauce. Regulatory documents also note that alcohol consumption may affect the body's process for eliminating the drug.

---

Q: Is Supracid considered the same type of drug as a general antacid?

No. Supracid is a Proton Pump Inhibitor (PPI), which works by blocking the production of acid at its source. This is different from a general antacid, which is designed to instantly neutralize the acid already present in the stomach.

---

Q: What is the difference between Supracid and other similar acid-reducing drugs?

As a Proton Pump Inhibitor, Supracid achieves profound and sustained acid suppression by permanently blocking the final step of acid secretion. Other acid-reducing medicines, such as H2 blockers, are described as offering a different mechanism of acid reduction.

---

Q: Does Supracid interact with over-the-counter pain relievers like ibuprofen?

Official drug interaction checkers state there is no known direct, clinically significant interaction between Supracid and ibuprofen. However, concurrent use of NSAIDs (like ibuprofen) is associated with an increased risk of gastrointestinal bleeding and ulceration, which is a known clinical consideration when these medicines are used concurrently.

---

Q: Is a metallic or altered taste mentioned as a possible side effect of Supracid?

Taste perversion (an altered or metallic taste) has been noted in postmarketing and clinical trial reports for the drug. This adverse event is considered to be one of the less common effects documented in the safety profile.

---

Q: Is there a boxed warning or special alert associated with Supracid?

Supracid does not carry a formal FDA Boxed Warning, which is the highest level of safety alert. However, the official labeling includes several Warnings and Precautions regarding potential serious risks such as bone fracture and kidney issues.

---

Q: What should a patient know about stopping Supracid after long-term use?

Official guidelines suggest that stopping the drug abruptly after long-term use may result in a temporary condition known as rebound acid hypersecretion. Official clinical guidelines often describe a process of gradually tapering the dose before ceasing therapy, which is intended to help manage this possibility.

---

Q: Can Supracid be taken with medications for high blood pressure?

Official drug interaction checkers indicate that there are no common, clinically significant interactions between Supracid and most major types of medications used for high blood pressure. The use of all concurrent medications is subject to professional review.

---

Q: Is it necessary to avoid alcohol completely while taking Supracid?

Official research indicates that alcohol consumption may affect the body's process for eliminating the drug. Because an interaction has been noted, the decision regarding the consumption of alcohol is based on professional guidance.

---

Q: Is Supracid available without a prescription in some areas?

The official regulatory status varies by country. While the higher-strength version of Supracid (Pantoprazole) is prescription-only, a lower-dose version of the active ingredient is available over-the-counter (OTC) in certain formulations in some regions.

---

Q: How is Supracid eliminated from the body?

Regulatory monographs state that the drug is primarily processed (metabolized) in the liver by the CYP450 enzyme system. Once metabolized, it is eliminated from the body largely through the urine and to a lesser extent, the feces.

---

Q: Why is Supracid not recommended for immediate, short-term relief?

The drug is not recommended for immediate relief because it needs to be absorbed into the bloodstream and travel to the stomach cells to physically block the acid pumps. It is designed for sustained acid suppression over time, not immediate neutralization of existing acid.

---

Q: Does taking Supracid affect the results of any common lab tests?

Official safety information notes that Supracid may cause false-positive results in urine screenings for Tetrahydrocannabinol (THC). The drug should be disclosed to the laboratory and prescribing professional before screening to ensure results are interpreted accurately.

---

Q: What specific warnings are given for patients with pre-existing heart conditions?

The official label contains a warning that long-term use may lead to Hypomagnesaemia (low magnesium). This condition is noted because it has been linked to potential serious cardiac events, such as an atypical or fast heart rate.

---

Q: Is fatigue or tiredness a commonly listed side effect of Supracid?

Tiredness or fatigue is documented in official regulatory data, being listed as an uncommon side effect (occurring in less than 1% of patients) in clinical trial and postmarketing reports.

---

Q: Has Supracid been linked to any respiratory side effects?

Respiratory side effects are mentioned in regulatory data from clinical trials. These reports include conditions like nasopharyngitis (inflammation of the nose and throat), cough, and pharyngitis (throat inflammation) being noted in some patients.

How to Store and Dispose of Supracid

Supracid (Sodium Bicarbonate) must be stored and disposed of according to official regulatory labeling to maintain stability and ensure safety.

Storage Requirements

Temperature and Protection: The medicine must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, which should be tightly closed to protect it from moisture and humidity. Do not freeze the medicine, and do not use it past the expiration date on the package.

Child Safety: It is mandatory to store Supracid out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Supracid should be discarded using an authorized drug take-back program. If one is unavailable, the product may be mixed with an undesirable material (like used coffee grounds) and sealed in a bag before being placed in the household trash. The medicine must not be flushed down the toilet or sink.